Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study | Zendy

A Majuri | Zendy; Merja Santaniemi | Zendy; K Rautio | Zendy; Anne Kunnari | Zendy; Johanna Vartiainen | Zendy; Aimo Ruokonen | Zendy; Y. Antero Kesäniemi | Zendy; Juha S. Tapanainen | Zendy; Olavi Ukkola | Zendy; Laure MorinPapunen | Zendy

Open Access

Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study

Author(s) -

A Majuri,

Merja Santaniemi,

K Rautio,

Anne Kunnari,

Johanna Vartiainen,

Aimo Ruokonen,

Y. Antero Kesäniemi,

Juha S. Tapanainen,

Olavi Ukkola,

Laure MorinPapunen

Publication year - 2007

Publication title -

european journal of endocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.897

H-Index - 148

eISSN - 1479-683X

pISSN - 0804-4643

DOI - 10.1530/eje.1.02331

Subject(s) - medicine , endocrinology , adiponectin , resistin , insulin resistance , ghrelin , polycystic ovary , insulin , adipokine , hormone

Abdominal obesity, insulin resistance and compensatory hyperinsulinaemia play a central role in the pathogenesis of the polycystic ovary syndrome (PCOS). Abdominal adipose tissue is a source of adipokines, such as adiponectin and resistin, both of which may be involved in the development of insulin resistance and chronic inflammation in PCOS. Ghrelin, an important regulatory peptide of food intake, may also play a role in metabolic disturbances related to PCOS. The aim of this study was to examine the effects of 4 months of treatment with the insulin sensitizer rosiglitazone on plasma adiponectin, resistin and ghrelin levels in overweight women with PCOS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research